Pfizer's Cancer Drug Deal and UnitedHealth's Comeback Potential

Pfizer's New Cancer Drug Deal

• 💡 Pfizer is set to pay up to $6 billion to license an experimental cancer drug from a Chinese biotech company, leading to a stock increase of about 1.31%.
• ⚠️ This deal is noted as being about double the cost of a similar deal Merck made the previous year.
• 📉 Despite the news, one investor expresses that Pfizer has been a poor-performing stock, with an average cost in the high 20s and a recent low in April around $21.59.
• 🤔 The sentiment is that a 1% jump on such news indicates little enthusiasm, suggesting it might be best ignored if not already invested.

Healthcare Sector Discussion

• 📊 The Investment Committee is debating the healthcare sector, with a focus on both Pfizer and UnitedHealth.
• 📌 While Pfizer's stock is showing gains, the overall sentiment for the stock is cautious due to its long-term performance.

UnitedHealth's Challenges and Recovery

• 📈 UnitedHealth is showing signs of recovery, extending gains after its best two-day rally since March 2020.
• 📉 The company has faced significant challenges, including a CEO resignation, pulling guidance, and an ongoing investigation, leading to a 36% year-to-date stock decline.
• 💰 Despite the turmoil, the stock now trades at nine times EBITDA, and the return of a former CEO who previously oversaw significant stock growth (350% rise between 2006-2017) is seen as a positive sign.
• 🎯 The company is still considered the number one managed care company globally, serving 151 million people, with future potential tied to Medicare Advantage repricing in 2026.
• ⏳ Investors acknowledge that while the stock is a long-term buy due to its fundamental strength, it will likely take time to regain its previous status, comparing the situation to Merck's recovery after a past crisis.
• ✅ One investor is happy about selling in April around $546, while acknowledging the stock's potential for a turnaround, albeit a slow one.